Q BioMed Inc. is a biomedical acceleration and development company. We are dedicated to acquiring and providing strategic resources and expansion capital to innovative healthcare companies that strive to provide much needed healthcare and related products to patients in need.
By partnering with exceptional entrepreneurs we aim to help to create market-leading products and companies in the biomedical and healthcare sector. As entrepreneurs and investors with operational and technical expertise we embrace a collaborative approach to capital formation and business development.
We have identified several targets that could provide a substantial pipeline of innovative and high value assets. Q intends to maximize risk-adjusted returns by focusing on clinical stage and innovative products where the technical, regulatory, and commercial risks have been mitigated or major valuation inflections are imminent.
Q and its investors are positioned to benefit from early investment in illiquid and unknown private assets with multiple potential products in their development cycle and capitalize on valuation growth as they move forward.
We expect success to be shared as multiple assets mature at different times in their development cycle passing on value to the Q BioMed shareholders."
Q BioMed investors will have the opportunity to realize the value created from our strategic investment of resources into innovative bio-medical products that they may never have known about. These technologies are vetted by analysts, industry KOLs and experts. As a public company, Q BioMed gives investors public company liquidity without being tied up in a private company or a single biotech asset with unknown exit strategy and uncertain value inflection milestones. Q BioMed plans to mitigate risk by licensing or acquiring multiple assets across a broad spectrum of healthcare related products, companies and sectors. We expect these assets to be developed to provide significant cash returns via organic cash flow or out-licensing, sale or be spun out into new public companies.